Document is current
Any future updates will be listed below
-
Authors
Gruber, Lars https://orcid.org/0009-0009-9955-1550
Schmidt, Stefan https://orcid.org/0000-0003-2896-3290
Enzlein, Thomas https://orcid.org/0000-0003-1789-4090
Vo, Huong Giang https://orcid.org/0009-0002-2025-6313
Bausbacher, Tobias https://orcid.org/0000-0003-4384-5612
Cairns, James Lucas https://orcid.org/0000-0003-4986-1015
Ucal, Yasemin
Keller, Florian
Kerndl, Martina
Sammour, Denis Abu https://orcid.org/0000-0003-1711-6854
Sharif, Omar https://orcid.org/0000-0001-7899-2343
Schabbauer, Gernot https://orcid.org/0000-0002-7490-8009
Rudolf, Rüdiger https://orcid.org/0000-0002-0833-1053
Eckhardt, Matthias https://orcid.org/0000-0003-1964-9064
Iakab, Stefania Alexandra https://orcid.org/0000-0002-4156-1942
Bindila, Laura https://orcid.org/0000-0001-5538-2008
Hopf, Carsten https://orcid.org/0000-0003-0802-6451
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (161L0212F, 12FH8I05IA, 13FH8I09IA)
Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg - Mittelbauprogramm
Christian Doppler Forschungsgesellschaft
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 7 May 2025
First Online: 22 May 2025
Competing interests
: Bruker Daltonics co-funded the BMBF-funded projects “Drugs4Future” and “DrugsData” within the framework M2Aind, as mandated by BMBF. All other authors declare no competing interests.
